close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nevro Corp. Common Stock (NY:NVRO)

5.840 UNCHANGED
Last Price Updated: 7:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nevro Corp. Common Stock

< Previous 1 2 3 4 5 Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗
 
Via Benzinga
Where Nevro Stands With Analysts ↗
 
Via Benzinga
News headline image
Nevro Secures FDA Nod HFX iQ Spinal Cord Stimulation System For to Personalize Pain Treatment ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Nevro ↗
Analysts have provided the following ratings for Nevro (NYSE:NVRO) within the last quarter: 
Via Benzinga
News headline image
Nevro Wins Multiple Coverage Options For Spinal Cord Stimulation In Diabetic Neuropathy ↗
 
Via Benzinga
News headline image
Nevro's Return On Capital Employed Overview ↗
  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Nevro's Return On Capital Employed Overview ↗
Benzinga Pro data, Nevro (NYSE:NVRO) reported Q1 sales of $87.84 million. Earnings fell to a loss of $34.33 million, resulting in a 13.91% decrease from last quarter. 
Via Benzinga
News headline image
Where Nevro Stands With Analysts ↗
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Expert Ratings For Nevro ↗
Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings: 
Via Benzinga
News headline image
Where Nevro Stands With Analysts ↗
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
News headline image
Recap: Nevro Q2 Earnings ↗
Nevro (NYSE:NVRO) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 13.41%,... 
Via Benzinga
News headline image
Expert Ratings for Nevro ↗
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
News headline image
Recap: Nevro Q1 Earnings ↗
Nevro (NYSE:NVRO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 10.91%,... 
Via Benzinga
News headline image
Recap: Nevro Q4 Earnings ↗
Nevro (NYSE:NVRO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
News headline image
Where Nevro Stands With Analysts ↗
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last ... 
Via Benzinga
4 Stocks Insiders Are Buying ↗
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
News headline image
Nevro: Q3 Earnings Insights ↗
Nevro (NYSE:NVRO) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro reported... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2022 ↗
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Craig-Hallum cut Zix Corporation (NASDAQ:ZIXI) p... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap... 
Via Benzinga
News headline image
Nevro Corp (NVRO) Q3 2021 Earnings Call Transcript ↗
NVRO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 ↗
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today